A sub-study to the EURO-SKI trial held by the Nordic CML study group (NCMLSG) reported that patients with high rates of mature (CD57+) and cytotoxic (CD16+ and CD57+) NK cells at the time of TKI discontinuation have higher possibility of successful TFR [93] and this suggests the importance of the surveillance of baseline immune markers before TKI discontinuation. Here, B3GAT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.